News

Tenax receives patent for TNX-103, oral levosimendan, for PH-HFpEF

Tenax Therapeutics has been issued a U.S. patent covering oral levosimendan, also known as TNX-103, for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The patent (U.S. Patent No. 11,701,355) is expected to provide intellectual property protection for TNX-103 through December 2040.

Air pollution exposure linked to PH, UK population study shows

Exposure to air pollutants significantly increased the risk of pulmonary hypertension (PH), according to a U.K. population study that included almost 500,000 people. Previous or current smoking increased PH risk and mortality even further, suggesting a synergistic relationship, the researchers noted. The large-scale study, “Dynamic association…

Zymedi and NHLBI collaborate to advance ZMA001 in PAH

Zymedi is collaborating with the National Heart, Lung, and Blood Institute (NHLBI) to advance the development of its first-in-class pulmonary arterial hypertension (PAH) treatment candidate ZMA001. The South Korea-based company and the NHLBI, part of the National Institutes of Health, have signed a clinical Cooperative Research and Development…

Experts call for referral protocols to improve PH care

Note: This story was corrected July 10, 2023, to reflect that attendees at the European Cardiac and Respiratory Societies discussed the therapy Tyvaso with regard to the 2022 pulmonary hypertension diagnosis and treatment guidelines. Pulmonary hypertension (PH) experts are calling for care protocols to expedite patient referrals to…

Algorithm acquires pump for PulmoProst, potential PAH therapy

Algorithm Sciences, which is developing PulmoProst to treat pulmonary arterial hypertension (PAH), has acquired all assets of Flownix Medical, including the Prometra II pump that would deliver the potential therapy. PulmoProst is an infusion formulation of iloprost, a synthetic version of naturally occurring prostacyclin, a substance that…

Liquidia licenses rights in North America to inhaled L606 for PH

Liquidia has licensed the rights in North America to L606, a novel inhaled formulation of treprostinil that’s being tested in trials of people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). “L606 is the perfect life-cycle complement to our pipeline and…

Janssen seeks approval in Europe for PAH combination therapy tablet

Janssen Pharmaceuticals has submitted an application in Europe asking regulatory authorities to approve the company’s combination therapy of macitentan and tadalafil — developed as a single tablet — for pulmonary arterial hypertension (PAH). The filing comes less than a month after Janssen submitted a similar application seeking approval…